Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT07442682
Enrolling by invitation Observational

Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center

NCT07442682 · tracked via the Priya Life Science Belgium tracker
Sponsor
Erasme University Hospital
Phase
Observational
Started
2025-12-11
Last updated
2026-03-02

Condition(s) studied

Quality of LifteCystic Fibrosis (CF)Diabetes

Study summary

This research project aims to better understand the consequences of diabetes on the quality of life, respiratory function, and nutritional status of patients with cystic fibrosis followed at a Belgian reference center and to compare the quality of life of patients with cystic fibrosis depending on whether or not they have diabetes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Adults ≥18 years Confirmed diagnosis of cystic fibrosis Followed at the participating CF reference center Ability to complete quality-of-life questionnaires Signed informed consent (if required by EC) \- Exclusion Criteria: Refusal to participate Inability to complete questionnaires

Primary outcome measure(s)

  • Comparison of quality of life between patients with cystic fibrosis according to the presence or absence of diabetes — cross-sectional assessment at study inclusion
    Use the Short Form Haelth Survey SF-36, a questionnaire comprising 36 items to compare quality of life in patients with CF according to the presence or absence of CFRD. Score scale ranges from 0 to 100. A higher score means a better quality of life.
  • Comparison of ppFEV₁ between patients with cystic fibrosis according to the presence or absence of diabetes. — FEV₁ data will be collected retrospectively from medical records, using the value closest to the time of study inclusion
    Predicted forced expiratory volume in 1 second (ppFEV1) FEV₁ values, obtained through pulmonary function testing, will be compared between cystic fibrosis patients according to the presence or absence of diabetes

Trial sites (1)

FacilityCityRegionStatus
Hôpital Erasme - HUB 808 route de Lennik 1070 Brussels Belgium Brussels Belgium

More Erasme University Hospital trials in Belgium

Transfusion Surveillance in Anaesthesia Recruiting
CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes Active, not recruiting
Respiratory and Haemodynamic Effects of Conscious Sedation With Dexmedetomidine for a TAVI Procedure Recruiting
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE) Recruiting
Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE) Recruiting

Other trials for the same condition

Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases Recruiting
Sweat Testing in Infants: Comparing Sweat Collection on Upper Vs Lower Limbs Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07442682 on ClinicalTrials.gov ↗ ← All trials in Belgium